Hemispherx BioPharma, Inc (HEB) Sees Large Decline in Short Interest
Hemispherx BioPharma, Inc (NYSE:HEB) saw a significant decrease in short interest in August. As of August 31st, there was short interest totalling 696,476 shares, a decrease of 27.8% from the August 15th total of 964,695 shares. Currently, 2.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 144,951 shares, the short-interest ratio is currently 4.8 days.
An institutional investor recently raised its position in Hemispherx BioPharma stock. Vanguard Group Inc. boosted its holdings in Hemispherx BioPharma, Inc (NYSE:HEB) by 0.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 453,805 shares of the specialty pharmaceutical company’s stock after buying an additional 2,709 shares during the period. Vanguard Group Inc. owned approximately 1.56% of Hemispherx BioPharma worth $227,000 as of its most recent SEC filing.
Hemispherx BioPharma (HEB) opened at 0.33 on Monday. The company’s market cap is $9.63 million. The firm has a 50 day moving average price of $0.38 and a 200 day moving average price of $0.50. Hemispherx BioPharma has a 12-month low of $0.30 and a 12-month high of $1.48.
Hemispherx BioPharma (NYSE:HEB) last announced its quarterly earnings data on Monday, August 14th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter. Hemispherx BioPharma had a negative net margin of 1,029.58% and a negative return on equity of 75.57%. The business had revenue of $0.21 million during the quarter.
COPYRIGHT VIOLATION WARNING: “Hemispherx BioPharma, Inc (HEB) Sees Large Decline in Short Interest” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/17/hemispherx-biopharma-inc-heb-sees-large-decline-in-short-interest.html.
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.
Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.